France says hepatitis B vaccine benefits outweigh multiple sclerosis risks
This article was originally published in Scrip
Executive Summary
The pharmacovigilance committee of France's medicines regulator, Afssaps, has discounted the risk of a possible association between vaccination against hepatitis B and the risk of a first central demyelinating event in children that might indicate the early stages of multiple sclerosis. It concluded at its meeting on September 30th that the available evidence did not alter the benefit/risk profile of hepatitis B vaccination.